Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sufentanil NanoTab

Small molecule · developed by Talphera

Phase 3 Most advanced trial (none active)
TLPH Developer
5 Registered trials

What is Sufentanil NanoTab?

Sufentanil NanoTab is a sufentanil sublingual tablet formulation given as-needed for acute pain.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ARX-F01
Drug type
Small molecule
Therapy area
Oncology
Developer
Talphera, Inc (TLPH)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01660763 Phase 3 Post Operative Pain Completed TLPH
NCT01710345 Phase 2 Acute Pain Completed TLPH
NCT00612534 Phase 2 Post Operative Pain Completed TLPH
NCT01721070 Phase 1 Pharmacokinetics Completed TLPH
NCT01639729 Phase 1 Pharmacokinetics Completed TLPH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute PainPharmacokineticsPost Operative Pain

More from Talphera

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TLPH page.

Follow TLPH, the company behind Sufentanil NanoTab

See TLPH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TLPH catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.